

References

- Wang, C., Ji, D., Chen, J., Shao, Q., Li, B., Liu, J., ... & Lu, L. (2017). Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. *Clinical Gastroenterology and Hepatology*, 15(1), 132-136.
- Keane, E., Funk, A. L., & Shimakawa, Y. (2016). Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Alimentary pharmacology & therapeutics*, 44(10), 1005-1017.
- Centers for Disease Control and Prevention. (2017). The ABCs of hepatitis. *South Carolina State Documents Depository*.
- Jourdain, G., Ngo-Giang-Huong, N., Harrison, L., Decker, L., Khamdang, W., Tierney, C., ... & Yuthavisuthi, P. (2018). Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. *New England Journal of Medicine*, 378(10), 911-923.
- Wang, C., Ma, D. Q., Luo, S., Wang, S. M., Ding, D. P., Tian, Y. Y., ... & Meng, Z. J. (2019). Incidence of infectious complications is associated with a high mortality in patients with hepatitis B virus-related acute-on-chronic liver failure. *World Journal of Clinical Cases*, 7(16), 2204.
- Konerman, M. A., & Lok, A. S. (2016). Interferon treatment for hepatitis B. *Clinics in liver disease*, 20(4), 645-665.
- Shire, N. J. (2017). Cure strategies for hepatitis B virus: the promise of immunotherapy. *Clinical Pharmacology in Drug Development*, 6(2), 186-194.